268 related articles for article (PubMed ID: 16014569)
1. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
[TBL] [Abstract][Full Text] [Related]
2. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
3. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.
Trbusek M; Malcikova J; Smardova J; Kuhrova V; Mentzlova D; Francova H; Bukovska S; Svitakova M; Kuglik P; Linkova V; Doubek M; Brychtova Y; Zacal J; Kujickova J; Pospisilova S; Dvorakova D; Vorlicek J; Mayer J
Leukemia; 2006 Jun; 20(6):1159-61. PubMed ID: 16572201
[No Abstract] [Full Text] [Related]
5. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
6. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
7. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
[TBL] [Abstract][Full Text] [Related]
8. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
Stankovic T; Hubank M; Cronin D; Stewart GS; Fletcher D; Bignell CR; Alvi AJ; Austen B; Weston VJ; Fegan C; Byrd PJ; Moss PA; Taylor AM
Blood; 2004 Jan; 103(1):291-300. PubMed ID: 12958068
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
[TBL] [Abstract][Full Text] [Related]
11. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
Guarini A; Marinelli M; Tavolaro S; Bellacchio E; Magliozzi M; Chiaretti S; De Propris MS; Peragine N; Santangelo S; Paoloni F; Nanni M; Del Giudice I; Mauro FR; Torrente I; Foà R
Haematologica; 2012 Jan; 97(1):47-55. PubMed ID: 21993670
[TBL] [Abstract][Full Text] [Related]
12. [Gene atm and chronic lymphocytic leukemia - review].
Zhu DX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1242-6. PubMed ID: 18928637
[TBL] [Abstract][Full Text] [Related]
13. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B; Lin TT; Ahmed G; Weston V; Jones RE; Fegan C; Oscier DG; Stankovic T; Pepper C; Baird DM
Leukemia; 2012 Apr; 26(4):826-30. PubMed ID: 21986843
[No Abstract] [Full Text] [Related]
14. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
17. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
[TBL] [Abstract][Full Text] [Related]
18. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
19. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
Greiner TC; Dasgupta C; Ho VV; Weisenburger DD; Smith LM; Lynch JC; Vose JM; Fu K; Armitage JO; Braziel RM; Campo E; Delabie J; Gascoyne RD; Jaffe ES; Muller-Hermelink HK; Ott G; Rosenwald A; Staudt LM; Im MY; Karaman MW; Pike BL; Chan WC; Hacia JG
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2352-7. PubMed ID: 16461462
[TBL] [Abstract][Full Text] [Related]
20. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
